Related Experiment Video
Updated: Jun 14, 2025
10:19
Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
Published on: May 12, 2023
1.2K
Exploring T-cell bispecific antibodies in gynecologic malignancy
Emily O'Brien1, Christopher M Mayer1, Rebecca C Arend1
1Department of Gynecologic Oncology, University of Alabama at Birmingham School of Medicine and O'Neal Comprehensive Cancer Center, Birmingham, AL, United States of America.
Gynecologic Oncology Reports
|June 12, 2025
Summary
T-cell bispecific antibodies (TCBs) show promise for treating gynecologic cancers by redirecting immune cells to attack tumors. Ongoing research and clinical trials are exploring their efficacy and safety for improved patient outcomes.
Area of Science:
- Oncology
- Immunology
- Women's Health
Background:
- Gynecologic cancers have high relapse rates with conventional treatments.
- Immunotherapy offers novel strategies for targeting and eliminating tumor cells.
- T-cell bispecific antibodies (TCBs) are an emerging immunotherapy class.
Purpose of the Study:
- To review T-cell bispecific antibodies (TCBs) for gynecologic malignancies.
- To discuss their mechanisms, preclinical and clinical data, and safety.
- To identify challenges and future directions for TCBs in this field.
Main Methods:
- Review of preclinical data on TCBs targeting AXL, MUC1, LYPD1, and MUC16.
- Analysis of ongoing clinical trials for MUC16-targeted TCBs in ovarian and endometrial cancers.
- Evaluation of TCB safety profiles, including cytokine release syndrome and on-target off-tumor toxicity.
Main Results:
- Preclinical studies show potent antitumor activity of TCBs against gynecologic cancers.
- Clinical trials are underway for MUC16-targeted TCBs in ovarian and endometrial cancers.
- TCBs have manageable safety profiles, with risks like cytokine release syndrome.
Conclusions:
- TCBs represent a promising immunotherapeutic approach for gynecologic cancers.
- Further research is needed to optimize TCB efficacy and safety.
- TCBs offer advantages over CAR T-cell therapy, such as being "off-the-shelf" products.
